HIQA: 177Lutetium PSMA radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer (2023-004): Evidence synthesis to support generic justification decision HIQA: 177Lutetium PSMA radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer (2023-004): Evidence synthesis to support generic justification decision
